Stryker Corporation (SYK) AI Stock Analysis

Stryker Corporation develops innovative medical technology solutions across two primary divisions: MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine unit provides implants for hip, knee, trauma, extremities, and spinal procedures. The MedSurg and Neurotechnology segment delivers surgical equipment, navigation platforms, endoscopic tools, patient handling devices, and emergency care products. It also provides neurotechnology devices for endovascular procedures, brain surgeries, and biosurgery applications. Founded in 1941 and based in Kalamazoo, Michigan, the company employs 56,000 people and distributes its devices globally through subsidiaries, branches, and third-party dealers.

Between FY2021 and FY2025, Stryker expanded annual revenue from $17.11B to $25.12B, reflecting an 11.8% five-year compound annual growth rate from FY2020. Annual net income grew from $1.99B in FY2021 to $3.25B in FY2025, while diluted earnings per share increased from $9.09 to $13.63. Gross margin stood at 64.0% in FY2025 compared to 62.6% in FY2021, and operating margin was 19.5%. For the trailing twelve months ended June 30, 2026, revenue totaled $25.84B with an operating margin of 27.0%. In the latest quarter ended June 30, 2026, quarterly revenue grew 9.4% year-over-year, while quarterly earnings expanded 44.1%.

As of June 30, 2026, Stryker held $3.48B in cash and short-term investments against $14.94B in total debt, resulting in net debt of $11.47B. Total assets stood at $47.93B and shareholders' equity was $23.99B, with a debt-to-equity ratio of 0.62 and a current ratio of 2.16. In FY2025, the company generated $5.04B in operating cash flow. Cash deployments included $761.0M in capital expenditures, $1.28B in dividends paid, and $149.0M in share buybacks, while share count changed by 0.9% over five years.

At $294.66, Stryker has a market cap of $113.02B and an enterprise value of $116.98B. The stock trades at a trailing price-to-earnings multiple of 30.5x, above the 27.2x median of its S&P 500 Healthcare peers. Its forward price-to-earnings ratio is 16.5x, matching closely with the peer median of 16.6x. Stryker carries an enterprise value to EBITDA multiple of 16.8x compared to the peer median of 15.0x, and a price-to-sales ratio of 4.4x versus 3.4x for peers. Over the trailing year, the stock fell 19.3%, trailing the S&P 500 return of 16.8%.

Stryker pays a quarterly dividend with an annualized forward payout of $3.52 per share, representing a 1.19% dividend yield. The company maintains a payout ratio of 25.2% and has paid dividends for 36 consecutive years. Over the last five years, the dividend grew at an annualized rate of 7.6%. Its last ex-dividend date was September 30, 2026.

Wall Street coverage includes 15 Strong Buy, 8 Buy, and 6 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $362.62, representing a 23.1% upside from the last close of $294.66. For FY2026, consensus estimates project revenue of $27.17B and earnings per share of $14.95, representing 9.7% earnings growth. Over the last four quarters, Stryker beat earnings estimates in 3 periods. The next earnings date is October 29, 2026.

This page is an AI-written research summary of Stryker Corporation (SYK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SYK income statement, SYK balance sheet, SYK key metrics, SYK analyst forecast, SYK chart. See the SYK stock overview for the latest quote and news.